Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

AstraZeneca's heart drug Brilinta fails in trial

Drug group said blood-thinning treatment missed targets for reducing repeat stroke and heart attacks
AstraZeneca's heart drug Brilinta fails in trial
Fewer people who took AstraZeneca's drug in the trial had a recurrent stroke, but not enough to hit targets

AstraZeneca PLC (LON:AZN) said stroke treatment Brilinta was not as effective as expected in trials, hitting hopes that it would be a flagship new drug.

AstraZeneca said a study of Brilinta/Brilique (ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA), had shown the drug had not met its primary efficacy endpoint of preventing repeat attacks within 90 days.

Fewer people who took AstraZeneca's drug in the trial had a recurrent stroke, heart attack or died than those on aspirin, but the difference was not statistically significant.

AstraZeneca's executive vice-president of global medicine development and chief medical officer, Sean Bohen, said: "We will present the full analysis of the trial results, including  subgroups, at a forthcoming stroke congress and will engage with regulatory agencies on the interpretation of the data."

The so-called Socrates trial evaluated the efficacy and safety of 90-day treatment with Brilinta/Brilique versus aspirin for the prevention of major vascular events in patients over 40 years-old with an acute ischaemic stroke.

Shares in AstraZeneca fell 3.5p to 3911.5p.

 

 

 

 

 

 

Phil-Waller.jpg


Register here to be notified of future AZN Company articles
View full AZN profile

AstraZeneca Timeline

Related Articles

Clean room
June 14 2016
Contracted business is already in excess of £9 million this year, with a strong pipeline of further business opportunities being pursued across all areas of the group
A graphic of a tumour growing in the body
July 07 2016
Nanobiotix is a late clinical-stage nanomedicine company researching novel approaches to enhance radiotherapy for the local treatment of cancer.
757z468_Lab-(1).jpg
April 26 2016
Dr Stewart White, Collagen Solutions chief executive, told investors that the new partnership will expedite the roll-out of its medical grade collagen to customers in China.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.